Benzene Ring Nonionically Bonded Patents (Class 514/568)
  • Patent number: 11446266
    Abstract: An intravenous composition for providing relief for pain and/or inflammation, the composition having ibuprofen and paracetamol in combination for delivering to a human at each dose: a) approximately 125 mg to approximately 175 mg ibuprofen in combination with approximately 475 mg to approximately 525 mg paracetamol; or b) approximately 275 mg to approximately 325 mg ibuprofen in combination with approximately 975 mg to approximately 1,025 mg paracetamol.
    Type: Grant
    Filed: October 1, 2018
    Date of Patent: September 20, 2022
    Assignee: AFT Pharmaceuticals Limited
    Inventor: Hartley C. Atkinson
  • Patent number: 11433040
    Abstract: The present disclosure provides compositions and methods for modifying endoplasmic reticulum trafficking of proteins. Also disclosed herein are methods for treating cancer and/or enhancing cancer or viral immunotherapy in a subject by increasing the extracellular secretion levels of GRP94 in the subject. Such methods comprise administering to the subject an effective amount of 4-PBA and/or a 4-PBA analog selected from among methoxy-PBA, 3-PPA, 5-PVA, hydroxy-PPA, hydroxy-PBA, and tolyl-BA.
    Type: Grant
    Filed: May 18, 2018
    Date of Patent: September 6, 2022
    Assignee: MEMORIAL SLOAN KETTERING CANCER CENTER
    Inventors: Jonathan Goldberg, Elena Goldberg, Wenfu Ma
  • Patent number: 11419803
    Abstract: The invention relates to a composition and a method of darkening human skin. The composition comprises select alkyl or alkyloxy benzoic acids.
    Type: Grant
    Filed: November 2, 2018
    Date of Patent: August 23, 2022
    Assignee: Conopco, Inc.
    Inventors: Sreenivasa Thimmaiah, Ian Peter Stott
  • Patent number: 11207292
    Abstract: Cannabidiol (CBD) is a cannabinoid designated chemically as 2-[(1R,6R)-3-Methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-benzenediol. Its empirical formula is C21H30O2 and its molecular weight is 314.46. CBD is a cannabinoid that naturally occurs in the Cannabis sativa L. plant. CBD is a white to pale yellow crystalline solid which is insoluble in water and soluble in organic solvents. The present invention encompasses the surprising recognition that certain CBD preparations which are prepared from a botanical origin are more effective in treating diseases or disorders than preparations of CBD which are synthetic or purified to the extent no other impurities in the form of other cannabinoids are present. Prior CBD compositions have been prepared such that no psychoactive components, e.g., tetrahydrocannabinol (THC), remain in the final CBD preparation. Surprisingly, the absence of such minor impurities reduces the efficacy of CBD treatment.
    Type: Grant
    Filed: September 3, 2020
    Date of Patent: December 28, 2021
    Assignee: GW Research Limited
    Inventors: Geoffrey Guy, Volker Knappertz, Benjamin Whalley, Marie Woolley-Roberts, James Brodie, Katarzyna Lach-Falcone, Alan Sutton, Royston Gray, Rohini Rajyalaxmi Rana
  • Patent number: 10912748
    Abstract: Disclosed herein are compositions including a compound of formula (I) for treating cancer. Some embodiments relate to methods of treating cancer by co-administering a compound of formula (I) and one or more immune checkpoint inhibitor to a subject in need thereof. Some embodiments relate to methods of treating cancer by co-administering a compound of formula (I) and plinabulin to a subject in need thereof. Some embodiments relate to methods of providing co-stimulation of T-cell activation against cancer by co-administering a compound of formula (I), one or more immune checkpoint inhibitor.
    Type: Grant
    Filed: February 6, 2017
    Date of Patent: February 9, 2021
    Assignee: BeyondSpring Pharmaceuticals, Inc.
    Inventors: Ramon Mohanlal, Lan Huang, George Kenneth Lloyd
  • Patent number: 10864182
    Abstract: Described herein is the use of sulindac in the treatment of fragile X syndrome (FXS).
    Type: Grant
    Filed: April 12, 2019
    Date of Patent: December 15, 2020
    Inventor: David Brown
  • Patent number: 10745382
    Abstract: The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases.
    Type: Grant
    Filed: October 11, 2016
    Date of Patent: August 18, 2020
    Assignee: bristol-myers squibb company
    Inventors: Kap-Sun Yeung, Timothy P. Connolly, David B. Frennesson, Katharine A. Grant-Young, Piyasena Hewawasam, David R. Langley, Zhaoxing Meng, Eric Mull, Kyle E. Parcella, Mark George Saulnier, Li-Qiang Sun, Alan Xiangdong Wang, Ningning Xu, Juliang Zhu, Paul Michael Scola
  • Patent number: 10537537
    Abstract: Methods of treating acute and chronic inflammatory conditions, tissue transplant rejection, and/or organ transplant rejection comprising administering to a subject in need thereof a therapeutically effective amount of a pluripotent anti-inflammatory and metabolic modulators optionally in combination with one or more secondary therapeutic agents and pharmaceutical compositions thereof.
    Type: Grant
    Filed: October 16, 2017
    Date of Patent: January 21, 2020
    Assignees: Institut Pasteur de Montevideo, Universidad de la República
    Inventors: Carlos Batthyány, Gloria Virginia López, Carlos Escande, Jorge Rodriguez Duarte, Williams Arturo Porcal Quinta, Rosina Dapueto Capuccio, Germán Adrian Galliussi López, María Pia Garat Nuñez, Marcelo Hill, Mercedes Segovia
  • Patent number: 10525054
    Abstract: The present invention relates generally to the co-administration of an opioid agonist compound and an analgesic compound. In addition, the invention relates to, among other things, dosage forms for co-administration of an opioid agonist compound and an analgesic compound, methods for administering an opioid agonist compound and an analgesic compound, compositions comprising an opioid agonist compound and an analgesic compound, dosage forms comprising an opioid agonist compound and an analgesic compound, and so on.
    Type: Grant
    Filed: February 9, 2018
    Date of Patent: January 7, 2020
    Assignee: Inheris Biopharma, Inc.
    Inventors: Timothy A. Riley, Juergen W. Pfeiffer, Hema Gursahani
  • Patent number: 10441553
    Abstract: The present invention relates to fluorine substituted CBD compounds, compositions thereof and uses thereof for the preparation of medicaments.
    Type: Grant
    Filed: August 1, 2017
    Date of Patent: October 15, 2019
    Assignees: UNIVERSIDADE DE SAO PAULO—USP, UNIVERSIDADE FEDERAL DO RIO GRANDE DO SUL—UFRGS, YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JESUSALEM LTD
    Inventors: Raphael Mechoulam, Antonio Waldo Zuardi, Flavio Pereira Kapczinski, Jaime Eduardo Cecilio Hallak, Francisco Silveira Guimaraes, Jose Alexandre de Souza Crippa, Aviva Breuer
  • Patent number: 10308583
    Abstract: The present invention provides compositions and method for production of shikimic acid based on extracts obtained from oil palm-based materials, and more particularly oil palm-based waste materials and by-products. The method includes purifying shikimic acid from extracts comprising oil palm phenolics (OPP).
    Type: Grant
    Filed: April 3, 2018
    Date of Patent: June 4, 2019
    Assignee: MALAYSIAN PALM OIL BOARD
    Inventors: Sambandan Tg, Chokyun Rha, Ravigadevi Sambanthamurthi, Anthony J. Sinskey, Yew Ai Tan, Kalyana Sundram P. Manickam, Mohd Basri Wahid
  • Patent number: 9987209
    Abstract: A composition is described that may be used in personal care products. The composition can serve as a preservative. In addition or alternatively, the composition may serve as a fragrance and/or as a coloring agent. The composition can contain an active compound, an organic acid, a solvent, and optionally a dispersant. In one embodiment, the active compound and the organic acid comprise all natural ingredients.
    Type: Grant
    Filed: April 9, 2014
    Date of Patent: June 5, 2018
    Assignee: Arch Chemicals, Inc.
    Inventors: Diana Ciccognani, Falen D. Lockett, Laura Szymczak
  • Patent number: 9919009
    Abstract: This disclosure provides methods of making a megakaryocyte-erythroid progenitor cell (MEP), comprising differentiating a stem cell into a MEP in culture in the presence of an aryl hydrocarbon receptor (AhR) agonist. In some embodiments the stem cell is a pluripotent stem cell. In some embodiments the MEP co-expresses CD41 and CD235. In some embodiments the number of MEPs produced in the culture increases exponentially. Methods of making a red blood cell (RBC) by culturing a MEP in the presence of an AhR agonist are also provided. Methods of making a megakaryocyte and/or a platelet, comprising culturing a MEP in the presence of an AhR modulator are also provided. In some embodiments the AhR modulator is an AhR antagonist. This disclosure also provides compositions comprising at least 1 million MEPs per ml and compositions in which at least 50% of the cells are MEPs.
    Type: Grant
    Filed: June 2, 2015
    Date of Patent: March 20, 2018
    Assignees: BOSTON MEDICAL CENTER CORPORATION, TRUSTEES OF BOSTON UNIVERSITY
    Inventors: George J. Murphy, David H. Sherr, Sarah S. Rozelle, Brenden W. Smith
  • Patent number: 9889097
    Abstract: The invention relates to a novel powder, it's method of manufacture and the use thereof in powder material processing, particularly in the manufacture of components formed from compacted powder e.g. discs, monoliths, layers or tablets. The powders comprise coated host particles wherein over 70% of the mass of the powder comprises coated particles smaller than 100 microns. The powders have particular application in the pharmaceutical industry and the technology described can be used to control the properties of active pharmaceutical ingredients. The powders (10) may comprise drug particles (12), carrier particles (14) and additives (16).
    Type: Grant
    Filed: June 19, 2008
    Date of Patent: February 13, 2018
    Assignee: NANO4M LIMITED
    Inventor: David Morton
  • Patent number: 9782360
    Abstract: The present invention relates to fluorine substituted CBD compounds, compositions thereof and uses thereof for the preparation of medicaments.
    Type: Grant
    Filed: August 19, 2016
    Date of Patent: October 10, 2017
    Assignees: UNIVERSIDADE DE SAO PAULO—USP, UNIVERSIDADE FEDERAL DO RIO GRANDE DO SUL—UFRGS, YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD
    Inventors: Raphael Mechoulam, Antonio Waldo Zuardi, Flavio Pereira Kapczinski, Jaime Eduardo Cecilio Hallak, Francisco Silveira Guimaraes, Jose Alexandre de Souza Crippa, Aviva Breuer
  • Patent number: 9763899
    Abstract: Formulations and methods are provided for improving the function, i.e. clinical outcome, of solid organ transplants. Lung transplantation is of particular interest. In the methods of the invention, a nanoparticle formulation comprising an effective dose of an iron chelator active agent in nanoparticle form, including without limitation, deferoxamine (DFO), deferasirox (DFX), and deferiprone (DFP), etc. is topically applied to the surface of tissues during episodes of graft rejection.
    Type: Grant
    Filed: December 18, 2013
    Date of Patent: September 19, 2017
    Assignees: The Board of Trustees of the Leland Stanford Junior University, The United States of America as Represented by the Department of Veterans Affairs, The Johns Hopkins University
    Inventors: Mark R. Nicolls, Xinguo Jiang, Geoffrey C. Gurtner, Gregg L. Semenza, Jayakumar Rajadas
  • Patent number: 9649285
    Abstract: The present invention provides for methods and compositions for treating medium chain acyl-CoA dehydrogenase deficiency. It is based, at least in part, on the discovery that phenylbutyrate can serve as a substrate for medium chain acyl-CoA dehydrogenase. In non-limiting embodiments, phenylbutyrate and/or another source of phenylacetate is administered as a chaperone treatment to patients suffering from medium chain acyl-CoA dehydrogenase deficiency.
    Type: Grant
    Filed: February 24, 2016
    Date of Patent: May 16, 2017
    Assignee: University of Pittsburgh-of the Commonwealth System of Higher Education
    Inventors: Al-Walid Mohsen Mohamed, Gerard Vockley
  • Patent number: 9370524
    Abstract: The present invention provides compositions and methods for increasing therapeutic gain in radiotherapy and chemotherapy for proliferating malignant or nonmalignant disease to produce high probability of tumor control with low frequency of sequelae of therapy by administering a therapeutically effective amount of a histone deacetylase inhibitor.
    Type: Grant
    Filed: March 11, 2004
    Date of Patent: June 21, 2016
    Assignee: Sunny Pharmatech Inc.
    Inventor: Yih-Lin Chung
  • Patent number: 9289409
    Abstract: Effective treatments of pain and/or inflammation for extended periods of time are provided. Through the administration of an effective amount of sulindac or a pharmaceutically acceptable salt thereof at or near a target site, one can relieve pain and/or inflammation caused by diverse sources, including but not limited to spinal disc herniation (i.e. sciatica), spondilothesis, stenosis, discongenic back pain and joint pain, as well as pain that is incidental to surgery. When appropriate formulations are provided within biodegradable polymers, this relief can be continued for at least three days, at least twenty-five days. In some embodiments, the relief can be for at least fifty days, at least one hundred days, at least one hundred and thirty-five days or at least one hundred and eighty days.
    Type: Grant
    Filed: March 27, 2009
    Date of Patent: March 22, 2016
    Assignee: Warsaw Orthopedic, Inc.
    Inventors: John Myers Zanella, Vanja M King, Christopher M Hobot, S Mark Cox, Danielle Biggs, Katara Shaw, William F McKay, Kathy L Remsen
  • Patent number: 9114165
    Abstract: Pharmaceutical composition of ibuprofen for injection that comprises an aqueous solution of ibuprofen and trometamol. These compositions display a minimal loss of active principle and acceptable increase of impurities after autoclaving, properties that have been demonstrated in various types of containers, such as containers made of plastics such as polypropylene, PVC and polyethylene, as well as in glass containers. These compositions, after undergoing autoclaving, still comply with all the relevant technical specifications of the European Pharmacopoeia and of the USP.
    Type: Grant
    Filed: May 18, 2011
    Date of Patent: August 25, 2015
    Assignee: Spain Pharma S.A.
    Inventors: Ignacio Ortúzar Andéchaga, Mario Ortúzar Gutiérrez
  • Patent number: 9102607
    Abstract: Compounds of the following general formula (I): are described. Also described, are processes of their preparation and their use in therapeutic applications.
    Type: Grant
    Filed: December 10, 2010
    Date of Patent: August 11, 2015
    Assignee: GALDERMA RESEARCH & DEVELOPMENT
    Inventors: Claire Bouix-Peter, Jean-Claude Pascal, Nicolas Rodeville
  • Patent number: 9090555
    Abstract: A compound of the general formula (I) is provided for use in the topical treatment of infection, inflammation and/or pain: wherein R1 independently represents a methylene group, an ethylene group or a straight or branched chain C3 to C6 alkylene group; R2 independently represents a hydrogen atom, a methyl group, an ethyl group or a straight or branched chain C3 to C20 alkyl group; x represents 0 or an integer from 1 to 4 and y represents 0 or an integer from 1 to 4, wherein the sum of x and y is 4; and Z represents a hydrogen atom or (HOR1)yR2XN+; compositions including the compound; use of the compound in the manufacture of a medicament; and methods of medical treatment including the topical application of the compound.
    Type: Grant
    Filed: July 2, 2014
    Date of Patent: July 28, 2015
    Inventor: Roy Arlington Jordan
  • Publication number: 20150141476
    Abstract: The present invention relates to the use of a 2,5-dihydroxybenzene derivative of formula (I) or a pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the treatment and/or prophylaxis of, inter alia, rosacea.
    Type: Application
    Filed: January 23, 2015
    Publication date: May 21, 2015
    Inventors: Pedro Cuevas Sànchez, Guillermo Gimenez Gallego, Inigo Saenz de Tejada Gorman, Javier Angulo Frutos, Serafin Valverde Lopez, Antonio Romero Garrido, Rosa Maria Lozano Puerto
  • Patent number: 9023892
    Abstract: A compound for use as an antimicrobial having a formula (A).
    Type: Grant
    Filed: December 21, 2010
    Date of Patent: May 5, 2015
    Inventors: Allan James McKinley, Thomas V. Riley, Nigel Lengkeek, Scott Stewart, Ramiz Boulos
  • Publication number: 20150119348
    Abstract: Natural occurring inhibitors of cyclin-dependent protein kinase 5 (Cdk5), isolated from the root of Rhodiola rosea are structurally different from the known Cdk inhibitors. They show selectivity among different Cdks and efficacy to inhibit Cdk via a mixed-type of inhibition, which should lead to less toxicity and side-effects. They are useful in preventing and treating diseases and disorders associated with aberrant Cdk5 activities, such as acute and/or chronic pain, neuropathic pain, diabetes mellitus, cancer, neurodegenerative diseases and neuropathological disorders.
    Type: Application
    Filed: December 30, 2014
    Publication date: April 30, 2015
    Inventors: Nancy Yuk-Yu IP, Fanny Chui-Fun IP, Wing Yu FU, Guangmiao FU
  • Publication number: 20150105338
    Abstract: The invention provides compositions comprising a therapeutically effective amount of a compound of general formula (I): wherein R1, R2 and R3 may be independently selected from H, OH and OMe; wherein X is C1 or C2 and wherein for C2 each carbon is linked by a single or multiple bond (preferably a double bond) and is substituted with one or more H or OH, for use as a medicament for treating or preventing the development of medical conditions characterised by inappropriate platelet aggregation. The compositions of the invention may be used to maintain heart health by reducing platelet aggregation; benefit the circulation; and/or normalize or otherwise benefit blood flow.
    Type: Application
    Filed: July 17, 2014
    Publication date: April 16, 2015
    Applicant: PROVEXIS NATURAL PRODUCTS LIMITED
    Inventor: Niamh O'Kennedy
  • Publication number: 20150099015
    Abstract: Methods and compositions are provided for treating neuropsychiatric disorders such as schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia, and bipolar disorder. The methods entail administering to a patient diagnosed as having a neuropsychiatric disorder (e.g., schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia bipolar disorder, etc.) or as at risk for a neuropsychiatric disorder a benzoic acid, benzoic acid salt, and/or benzoic acid derivative, and/or a sorbic acid, sorbic acid salt, and/or sorbic acid derivative, in combination with a neuropharmacological agent (e.g., an antipsychotic, an antidepressant, medications for attention deficit and hyperactivity disorder, cognitive impairment, or dementia, etc.) where the benzoic acid, benzoic acid salt, or benzoic acid derivative, and/or a sorbic acid, sorbic acid salt, and/or sorbic acid derivative, is in an amount sufficient to increase the efficacy of the neuropharmacological agent.
    Type: Application
    Filed: November 24, 2014
    Publication date: April 9, 2015
    Inventor: Guochuan Emil TSAI
  • Publication number: 20150093378
    Abstract: Disclosed herein are methods for treating type 2 diabetes, limiting development of type 2 diabetes, and treating a pre-diabetic state by administering to a subject in need thereof a GPBP inhibitor. Also disclosed herein are methods for diagnosing a pre-diabetic state and for diagnosing a propensity to develop type 2 diabetes by determining an amount of GPBP in a sample from a subject and comparing to control.
    Type: Application
    Filed: September 26, 2014
    Publication date: April 2, 2015
    Inventors: Juan SAUS, Fernando REVERT, Francisco REVERT-ROS
  • Publication number: 20150094278
    Abstract: The present disclosure provides methods, systems, and instruments for the determination by a physician or medical professional whether a subject is experiencing or has recently experienced an overt HE episode and for grading overt HE episodes as well as methods, systems, instruments and tools for screening for overt HE episodes by a non-medical professional such as a caregiver. Also provided are methods of treating HE episodes and methods of monitoring HE episode treatment that incorporate these methods, systems, instruments, and tools.
    Type: Application
    Filed: September 30, 2014
    Publication date: April 2, 2015
    Inventors: Bruce SCHARSCHMIDT, Masoud MOKHTARANI, Marzena JUREK
  • Publication number: 20150065573
    Abstract: A method of treating age-related macular degeneration. The method includes the step of administering orally or parenterally an effective amount of aurin tricarboxylic acid, aurin quadracarboxylic acid, and/or aurin hexacarboxylic acid, wherein the method excludes administration of components of aurin tricarboxylic acid complex of greater than or equal to 1 kilodalton in molecular weight.
    Type: Application
    Filed: November 10, 2014
    Publication date: March 5, 2015
    Inventors: Patrick L. McGeer, Moonhee Lee
  • Publication number: 20150065574
    Abstract: A method of treating atypical hemolytic uremic syndrome. The method includes the step of administering orally or parenterally an effective amount of aurin tricarboxylic acid, aurin quadracarboxylic acid, and/or aurin hexacarboxylic acid, wherein the method excludes administration of components of aurin tricarboxylic acid complex of greater than or equal to 1 kilodalton in molecular weight.
    Type: Application
    Filed: November 10, 2014
    Publication date: March 5, 2015
    Inventors: Patrick L. McGeer, Moonhee Lee
  • Publication number: 20150038567
    Abstract: The invention relates to a compound selected from the group consisting of all stereoisomers and their mixtures of the compounds of general formulas (1)-(4), in which R1 is a straight-chained, branched or cyclic hydrocarbon group with up to 12 C-atoms and X+ is selected from the group consisting of H+, NH4+, mono, di or trivalent metal cations, NH4+, primary, secondary, tertiary or quaternary organic ammonium ions with up to 48 C-atoms, which can carry even more functional groups, hydrazinium ion (N2H5+), hydroxylammonium ion (NH3OH+), guanidinium ion (CN3H6+), and organic derivatives of (N2H5+), NH3OH+, and CN3H6+, which can carry even more functional groups, and similar.
    Type: Application
    Filed: October 1, 2012
    Publication date: February 5, 2015
    Applicant: THE HEALTH CONCEPT GMBH
    Inventors: Thomas Herkenroth, Christian Steup
  • Patent number: 8946295
    Abstract: A method for promoting wound healing and preventing scar formation in a variety of wounds in skin, mucosa, and cornea. The method comprises administering a therapeutically effective amount of a histone deacetylase inhibitor or a hyperacetylating agent. The histone deacetylase inhibitor or hyperacetylating agent is capable of stimulating multiple cytokines/growth factors in the early phase of wound healing, and suppressing fibrogenic cytokines/growth factors in the late phase of tissue remodeling in the wound site, and is useful in promoting epithelial cell re-growth and reducing excessive collagen accumulation, which results in rapid wound closure with reduced scaring.
    Type: Grant
    Filed: May 10, 2004
    Date of Patent: February 3, 2015
    Assignee: Sunny Pharmtech Inc.
    Inventor: Yih-Lin Chung
  • Publication number: 20150005383
    Abstract: A compound of the general formula (I) is provided for use in the topical treatment of infection, inflammation and/or pain: wherein R1 independently represents a methylene group, an ethylene group or a straight or branched chain C3 to C6 alkylene group; R2 independently represents a hydrogen atom, a methyl group, an ethyl group or a straight or branched chain C3 to C20 alkyl group; x represents 0 or an integer from 1 to 4 and y represents 0 or an integer from 1 to 4, wherein the sum of x and y is 4; and Z represents a hydrogen atom or (HOR1)yR2XN+; compositions including the compound; use of the compound in the manufacture of a medicament; and methods of medical treatment including the topical application of the compound.
    Type: Application
    Filed: July 2, 2014
    Publication date: January 1, 2015
    Inventor: Roy Arlington Jordan
  • Publication number: 20150004216
    Abstract: A medicant composition is provided. The composition includes a film layer and a powder matrix layer. The powder matrix layer includes a medicant. The powder matrix layer is applied to the film layer by admixing particulate to form a powder matrix and by then applying the powder matrix to the film layer by any desired method. The composition of the powder matrix is varied to alter the dissolution rate of the medicant, the adhesion of the medicant composition, and other physical properties of the powder matrix. The powder matrix layer can be cured.
    Type: Application
    Filed: September 19, 2014
    Publication date: January 1, 2015
    Inventor: Robert Steven Davidson
  • Patent number: 8920821
    Abstract: The present invention relates to a topical composition which includes a bioactive drug formulated with silica in the form of microspheres, or drugs in a combination with the silica microspheres in an oily suspension, gel or emulsion. The topical compositions of the invention provide sustained release of a bioactive drug so as to reduce skin irritation.
    Type: Grant
    Filed: April 12, 2007
    Date of Patent: December 30, 2014
    Assignee: Perrigo Israel Pharmaceuticals Ltd.
    Inventors: Nir Avram, Marina Shevachman, Amira Ze'evi, Eilon Asculai, Batella Binyaminovich
  • Publication number: 20140371232
    Abstract: Provided are cajanine structure analogous compounds, synthesis method and pharmacological effects thereof, the compounds of the present invention having the structure as represented by general formulas I, II, III, IV and V. Also provided are pharmaceutical compositions containing the compounds as active ingredient, and uses thereof; the compounds of the present invention having the pharmacological activities such as anti-virus, anti-virus-infection, nerve protection, anti-metabolic-diseases and the like. Also provided is a chemical total synthesis preparation method of the natural products cajanine, cajanine A and cajanine C. The present invention lays a foundation for the in-depth study and development of the compounds as clinical drugs in the future.
    Type: Application
    Filed: December 18, 2012
    Publication date: December 18, 2014
    Inventors: Zhuorong Li, Xingyue Ji, Situ Xue, Guanghui Zheng, Yuhuan Li, Peizhen Tao, Jiandong Jiang
  • Publication number: 20140371692
    Abstract: Hydrogel compositions are provided (a) that have a continuous hydrophobic phase and a discontinuous hydrophilic phase, (b) that have a discontinuous hydrophilic phase and a continuous hydrophilic phase, or (c) that are entirely composed of a continuous hydrophilic phase. The hydrophobic phase, if present, is composed of a hydrophobic polymer, particularly a hydrophobic pressure-sensitive adhesive (PSA), a plasticizing elastomer, a tackifying resin, and an optional antioxidant. The discontinuous hydrophilic phase, if present, is composed of a crosslinked hydrophilic polymer, particularly a crosslinked cellulosic polymer such as crosslinked sodium carboxymethylcellulose. For those hydrogel compositions containing a continuous hydrophilic phase, the components of the phase include a cellulose ester composition or an acrylate polymer or copolymer, and a blend of a hydrophilic polymer and a complementary oligomer capable of hydrogen bonding thereto.
    Type: Application
    Filed: April 29, 2014
    Publication date: December 18, 2014
    Applicants: A.V. TOPCHIEV INSTITUTE OF PETROCHEMICAL SYNTHESIS RUSSIAN ACADEMY OF SCIENCES, CORIUM INTERNATIONAL, INC.
    Inventors: Gary W. Cleary, Shoreh Parandoosh, Mikhail M. Feldstein, Anatoly E. Chalykh, Nicolai A. Platè, Valery G. Kulichikhin
  • Publication number: 20140364391
    Abstract: The invention provides methods of immobilizing an active agent to a substrate surface, including the steps of, providing a substrate, contacting the substrate with a solution of a compound including a trihydroxyphenyl group, thereby forming a trihydroxyphenyl-treated substrate, and contacting the trihydroxyphenyl-treated substrate with an active agent, thereby immobilizing the active agent on the substrate. Further provided are methods of immobilizing an active agent on a substrate, including the steps of providing a substrate, combining a solution of a compound including a trihydroxyphenyl group with a solution of an active agent, thereby forming a solution of an active agent-trihydroxyphenyl conjugate, and contacting the substrate with the solution of the active agent-trihydroxyphenyl conjugate, thereby immobilizing the active agent on the substrate. The invention further provides substrates and medical device or device components with active agents immobilized on the surface thereof.
    Type: Application
    Filed: June 6, 2014
    Publication date: December 11, 2014
    Applicants: BAXTER INTERNATIONAL INC., BAXTER HEALTHCARE SA, NORTHWESTERN UNIVERSITY
    Inventors: Ton That Hai, John-Bruce Devault Green, Timothy Michael Fulghum, Phillip Byron Messersmith, Tadas Stanislovas Sileika
  • Patent number: 8906958
    Abstract: The invention relates to certain compounds, salts of these compounds and mixtures containing or consisting of two or more such compounds, two or more such salts or one or more such compounds and one or more such salts, each for use in a method for the prophylaxis and/or treatment of inflammation, in particular of inflammation of the skin.
    Type: Grant
    Filed: February 27, 2013
    Date of Patent: December 9, 2014
    Assignee: Symrise AG
    Inventors: Katharina Reichelt, Jakob Ley, Marcus Götz, Maria Blings
  • Publication number: 20140356455
    Abstract: Methods of generating cell lines with a sequence variation or copy number variation of a gene of interest, methods of use thereof, and cell lines with a sequence variation or copy number variation of a gene of interest are provided.
    Type: Application
    Filed: December 6, 2013
    Publication date: December 4, 2014
    Applicants: The Board of Trustees of the Leland Stanford Junior University, Parkinson's Institute
    Inventors: Renee Ann Reijo Pera, J. William Langston, Birgitt Schule, Theodore D. Palmer, Blake Byers, Ha Nam Nguyen, James Anthony Byrne, Branden John Cord
  • Publication number: 20140343155
    Abstract: The present invention relates to a method of disinfecting a surface and to an antimicrobial composition. Essential oils, which are used as antimicrobial actives, are also known for their strong odour; using high amounts of these gives a strong smell to the product that is not always appreciated by the consumer. It is therefore an object of the invention to provide an antimicrobial composition, having good anti-microbial properties, at very low levels of essential oil actives. The present inventors have achieved this using a synergistic combination of select anti-microbial actives and select hydrotropes.
    Type: Application
    Filed: November 21, 2012
    Publication date: November 20, 2014
    Applicant: Conopco, Inc., d/b/a UNILEVER
    Inventors: Sujatha Jayaraman, Shanthi Appavoo, Sujitkumar Suresh Hibare, Vidula Iyer, Maya Treesa Saji
  • Publication number: 20140343107
    Abstract: The invention provides retinoic acid receptor (RAR) selective agonists and formulations thereof for the treatment of disease or for inducing a medically beneficial effect.
    Type: Application
    Filed: May 23, 2014
    Publication date: November 20, 2014
    Applicant: QuRetino Therapeutics, Inc.
    Inventor: Ferenc Makra
  • Publication number: 20140336257
    Abstract: A regimen for the safe and effective long-term treatment of acne vulgaris entails topically applying onto the affected skin area of a subject afflicted therewith, for a period of time of at least four (4) months, e.g., for at least twelve (12) months and advantageously on a daily basis and preferably once a day, a thus effective amount of a topical medicament containing adapalene and benzoyl peroxide, formulated into a pharmaceutically acceptable medium therefor.
    Type: Application
    Filed: July 22, 2014
    Publication date: November 13, 2014
    Inventors: Michael GRAEBER, Yin LIU, Barbara GORE
  • Publication number: 20140336254
    Abstract: A family of covalent kinetic stabilizer compounds that selectively and covalently react with the prominent plasma protein transthyretin in preference to more than 4000 other human plasma proteins is disclosed. A contemplated compound corresponds in structure to Formula I, below, where the various substituents are defined within, and reacts chemoselectively with one or two of four Lys-15 ?-amino groups within the transthyretin tetramer. The crystal structure confirms the binding orientation of the compound substructure and the conjugating amide bond. A covalent transthyretin kinetic stabilizer exhibits superior amyloid inhibition potency, compared to a non-covalent counterpart, and inhibits cytotoxicity associated with amyloidogenesis.
    Type: Application
    Filed: April 14, 2014
    Publication date: November 13, 2014
    Inventors: Jeffery W. Kelly, Sungwook Choi
  • Publication number: 20140336136
    Abstract: The present invention relates to the use of certain stilbene derivatives for cosmetic and dermatological applications, in particular prevention and/or treatment of skin aging, as well as to cosmetic and dermatological compositions containing such stilbene derivatives.
    Type: Application
    Filed: May 7, 2014
    Publication date: November 13, 2014
    Applicant: RAHN AG
    Inventors: Jens Bitzer, Thomas Küper, Philipp Wabnitz
  • Publication number: 20140336258
    Abstract: A method of reducing the virulence of a bacterium that expresses accessory gene regulator A (AgrA) includes administering to the bacterium an amount of AgrA antagonist effective to inhibit the synthesis of one or more virulence factors by the bacterium.
    Type: Application
    Filed: July 29, 2014
    Publication date: November 13, 2014
    Inventor: Menachem Shoham
  • Publication number: 20140336259
    Abstract: The present document describes a phytochemical isolated from maple syrup and composition comprising the same. More specifically, the document describes an antioxidant phytochemical compound, derivates thereof, and composition comprising the same. The document also describes a process of synthesizing the antioxidant phytochemical compound.
    Type: Application
    Filed: June 11, 2012
    Publication date: November 13, 2014
    Inventors: Navindra Seeram, Julie Barbeau, Genevieve BeLand, Keykavous Parang
  • Publication number: 20140328902
    Abstract: This disclosure provides generally for antimicrobial compositions and methods of use comprising an anthocyanin, an anthocyanidin or metabolites thereof. Methods for promoting healing of a wound using these compositions are also disclosed. These compositions have broad spectrum antimicrobial activity and are safe for human and animal uses. Further, these compositions are safe for medical uses and industrial uses as antiseptic preparations to reduce or prevent microbial growth.
    Type: Application
    Filed: April 29, 2014
    Publication date: November 6, 2014
    Inventor: Lanny Leo Johnson
  • Patent number: 8877808
    Abstract: This invention describes a method of preventing and treating inflammatory skin diseases by topical application of aurin tricarboxylic acid and its derivatives. Such diseases are characterized by immune attack, especially involving aberrant complement activation. The diseases include, but are not limited to, androgenetic alopecia (baldness), seborrheic dermatitis/dandruff, allergic dermatitis, primary cicatricial alopecia, pemphigus, psoriasis, discoid lupus erythematosis, and dermatitus herpetiformis.
    Type: Grant
    Filed: December 6, 2012
    Date of Patent: November 4, 2014
    Assignee: Aurin Biotech Inc.
    Inventors: Patrick L. McGeer, Moonhee Lee, Douglas N. Bell